GH · Guardant Health, Inc.

The thesis

Guardant Health's Shield blood test cleared the third-quarter (Q3) test, but the case for the shares beating the market over the next three months has weakened. Patent rulings and wider cash-burn guidance now compete with the revenue growth, and the fourth-quarter report, expected around 18 February 2027, settles whether new coverage becomes revenue.

Screening revenue was $67.6 million in Q3, above the $52.9 million for Q2, on 83,000 Shield tests against about 66,000, according to the company's 5 November 2026 results. Guardant also raised 2026 revenue guidance for the third time, to $1.36–1.37 billion.

The shares did not confirm it. Adjusted daily closes fell from $182.59 on 28 October 2026 to $153.43 on 5 November 2026, before the report, and that close sits under the $161.41 invalidation level in the previous note. An Investing.com headline then described a 12% fall as cash burn guidance disappointed. The first close after the report was not available at the time of writing, and company news offers no single explanation for the slide before it.

The narrative is maturing: Guardant's 5 November 2026 release puts Shield coverage above 80% of eligible lives, so coverage news is largely spent and attention has moved to conversion, cash and the patent dispute.

Bullish and bearish views on Guardant Health, Inc.

The bull case on Guardant Health, Inc. (GH), in brief: Shield volume and revenue accelerated. The bear case: Patent losses keep accumulating.

Bull case

• Shield volume and revenue accelerated. Q3 Shield tests rose 246% to 83,000 and screening revenue rose 180% to $67.6 million, per the 5 November 2026 release. Guidance moved to $233–238 million of screening revenue and 285,000–290,000 tests, from $218–230 million and 270,000–285,000.
• Shield unit costs fell early. The chief financial officer said on the 5 November 2026 call that cost per test was $330 in Q3, down from $410 in Q2. That beat the $350 year-end target a quarter ahead, and the goal is $200 by the end of 2028.
• The cash-burn increase is mostly timing. Guardant blamed a Medicare claims delay on the new billing code for Guardant360 Liquid CDx, which shifts $10–15 million of payments into the first half of 2027, per the 5 November 2026 call. The company still targets free cash flow breakeven by the end of 2027 and held $1.1 billion in cash at 30 September 2026.
• Oncology volume remains strong. Q3 oncology tests rose 58% to 117,000 and oncology revenue rose 25% to $231.3 million, per the 5 November 2026 release. Guardant also submitted Guardant360 Tissue for US Food and Drug Administration approval and expects the Reveal Ultra clinical launch by year-end.
• Coverage is still ahead of revenue. UnitedHealthcare coverage has been in place since 1 August 2026, per the 5 November 2026 call. Carelon starts 15 November 2026 and EviCore 1 January 2027, per company releases, and management expects screening to reach an inflection point in 2027.

Bear case

• Patent losses keep accumulating. TwinStrand Biosciences said a US Patent and Trademark Office notice dated 4 November 2026 confirmed all 23 claims of its '631 patent, after the 14 October 2026 ruling upholding all 30 claims of its '127 patent. The Delaware court's August 2026 final judgment of $245.2 million is stayed pending appeal and carries a 6% ongoing royalty on 11 Guardant products through 15 March 2033, per TwinStrand.
• Cash burn guidance widened. Guardant raised 2026 free cash flow burn to $205–220 million from $195–205 million on 5 November 2026. Non-GAAP operating expense guidance also rose, to $1.105–1.125 billion from $1.080–1.100 billion.
• Shield pricing is set to slip. Management said on the 5 November 2026 call that average selling price, above $800 in Q3, should tick down toward a stated floor of $700 as commercially insured patients under 65 grow. UnitedHealthcare contract talks have started and no pricing terms exist yet.
• Coverage will take time to appear. Management said on the 5 November 2026 call that coverage gains will take "some time" to show in the numbers, and it gave no fourth-quarter Shield volume figure.
• The size of the beat is disputed. Benzinga compared Q3 revenue of $360.975 million with a $350.358 million estimate, while GuruFocus compared it with $368.53 million. Benzinga put the 2026 consensus at $1.357 billion, just below the new guidance range.
• The company still reports losses. Q3 net loss was $124.4 million and adjusted loss per share was $(0.29), per the 5 November 2026 release, so there is no earnings multiple to support the shares.

Price setup

The 5 November 2026 close of $153.43 is 18.0% below the 52-week high of $187.22, on adjusted daily closes. The shares are down 8.2% over three months, and the 14-day relative strength index (a 0–100 momentum gauge) reads 46.6, down from 66.6 at the prior note.

The September advance has been given back. The 4 September 2026 close was $161.41 and the 15 October 2026 close was $165.88.

Crowding has eased, with momentum now neutral and the earnings date past. Two supply items remain visible: the securities registration filed 30 July 2026 with no size disclosed, and performance-based stock awards to the co-chief executives announced 3 November 2026. Pre-report analyst targets stand well above the shares: UBS at $225 (9 September 2026), Barclays at $220 (7 October 2026) and BTIG at $210 (27 October 2026).

Catalysts, next 30 days

• 15 November 2026: Carelon Shield coverage takes effect. Any effect first appears in fourth-quarter results.
• By 31 December 2026: Reveal Ultra clinical launch, on management's year-end timetable.
• 1 January 2027: EviCore Shield coverage takes effect.
• January 2027: Medicare's claims system adds the Guardant360 Liquid CDx code, per the company, starting release of the delayed payments.
• ~18 February 2027, est.: Fourth-quarter report. It shows whether screening revenue lands inside $233–238 million for the year and what 2027 guidance implies for Shield.

The Federal Circuit appeal has no published decision date.

What would change the view

A court ruling or clarification placing Shield inside TwinStrand's 6% royalty products would break the case for Shield economics. So would full-year screening revenue below the $233 million low end of guidance, or a Shield selling price falling under management's $700 floor.

On price, a weekly close below $125 would take the shares well past the 12% post-report fall Investing.com described and would end the case.

The cautious three-month read would be wrong if the shares post a weekly close back above $161.41 and the fourth-quarter report puts full-year screening revenue at or above $238 million. A favorable appellate ruling on the $245.2 million judgment would have the same effect.

What it trades with

The recent drivers are specific to Guardant: the 14 October 2026 and 4 November 2026 patent outcomes and the 5 November 2026 cash guidance apply to no peer. Natera and Tempus AI are the closest comparisons among loss-making diagnostics companies; a fall in both while revenue estimates hold would point to a sector valuation move. Quest Diagnostics is both a Shield distribution partner and a competing lab, so its comments on Shield blood-draw volume bear directly on the screening forecast.